Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Koen B Pouwels

Showing results (81-90 of 101) with videos related to

Pageof 11
Sort By:
Nature Medicine|October 15, 2021
Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UKKoen B Pouwels, Emma Pritchard, Philippa C Matthews, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|October 6, 2023
A systematic review on the excess health risk of antibiotic-resistant bloodstream infections for six key pathogens in EuropeNasreen Hassoun-Kheir, Mariana Guedes, Marie-Therese Ngo Nsoga, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|December 21, 2023
Excess resource use and cost of drug-resistant infections for six key pathogens in Europe: a systematic review and Bayesian meta-analysisRhys Kingston, Venanzio Vella, Koen B Pouwels, et al.
Elife|July 12, 2021
Ct threshold values, a proxy for viral load in community SARS-CoV-2 cases, demonstrate wide variation across populations and over timeA Sarah Walker, Emma Pritchard, Thomas House, et al.
Nature Medicine|June 10, 2021
Impact of vaccination on new SARS-CoV-2 infections in the United KingdomEmma Pritchard, Philippa C Matthews, Nicole Stoesser, et al.
The Lancet. Global Health|January 10, 2026
Health-economic impacts of age-targeted and sex-targeted Lassa fever vaccination in endemic regions of Nigeria, Guinea, Liberia, and Sierra Leone: a modelling studyDavid R M Smith, Mary Chriselda Antony Oliver, Katherine M Holohan, et al.
Nature Communications|May 16, 2023
Protection against SARS-CoV-2 Omicron BA.4/5 variant following booster vaccination or breakthrough infection in the UKJia Wei, Philippa C Matthews, Nicole Stoesser, et al.
The Lancet Regional Health. Europe|December 20, 2021
Monitoring populations at increased risk for SARS-CoV-2 infection in the community using population-level demographic and behavioural surveillanceEmma Pritchard, Joel Jones, Karina-Doris Vihta, et al.
Nature Medicine|February 15, 2022
Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccinesJia Wei, Koen B Pouwels, Nicole Stoesser, et al.
Nature Communications|June 29, 2022
SARS-CoV-2 antibody trajectories after a single COVID-19 vaccination with and without prior infectionJia Wei, Philippa C Matthews, Nicole Stoesser, et al.
Pageof 11

Showing results (81-90 of 101) with videos related to

Sort By:
Pageof 11
Nature Medicine|October 15, 2021
Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UKKoen B Pouwels, Emma Pritchard, Philippa C Matthews, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|October 6, 2023
A systematic review on the excess health risk of antibiotic-resistant bloodstream infections for six key pathogens in EuropeNasreen Hassoun-Kheir, Mariana Guedes, Marie-Therese Ngo Nsoga, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|December 21, 2023
Excess resource use and cost of drug-resistant infections for six key pathogens in Europe: a systematic review and Bayesian meta-analysisRhys Kingston, Venanzio Vella, Koen B Pouwels, et al.
Elife|July 12, 2021
Ct threshold values, a proxy for viral load in community SARS-CoV-2 cases, demonstrate wide variation across populations and over timeA Sarah Walker, Emma Pritchard, Thomas House, et al.
Nature Medicine|June 10, 2021
Impact of vaccination on new SARS-CoV-2 infections in the United KingdomEmma Pritchard, Philippa C Matthews, Nicole Stoesser, et al.
The Lancet. Global Health|January 10, 2026
Health-economic impacts of age-targeted and sex-targeted Lassa fever vaccination in endemic regions of Nigeria, Guinea, Liberia, and Sierra Leone: a modelling studyDavid R M Smith, Mary Chriselda Antony Oliver, Katherine M Holohan, et al.
Nature Communications|May 16, 2023
Protection against SARS-CoV-2 Omicron BA.4/5 variant following booster vaccination or breakthrough infection in the UKJia Wei, Philippa C Matthews, Nicole Stoesser, et al.
The Lancet Regional Health. Europe|December 20, 2021
Monitoring populations at increased risk for SARS-CoV-2 infection in the community using population-level demographic and behavioural surveillanceEmma Pritchard, Joel Jones, Karina-Doris Vihta, et al.
Nature Medicine|February 15, 2022
Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccinesJia Wei, Koen B Pouwels, Nicole Stoesser, et al.
Nature Communications|June 29, 2022
SARS-CoV-2 antibody trajectories after a single COVID-19 vaccination with and without prior infectionJia Wei, Philippa C Matthews, Nicole Stoesser, et al.
Pageof 11